Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Andrews, Jennifer G.a; * | Lamb, Molly M.b | Conway, Kristinc | Street, Natalied | Westfield, Christinae | Ciafaloni, Emmaf | Matthews, Dennisg | Cunniff, Christopherh | Pandya, Shreef | Fox, Deborah J.e | MD STARneti
Affiliations: [a] Department of Pediatrics, University of Arizona, Tucson, Arizona, USA | [b] Department of Epidemiology, Colorado School of Public Health, University of Colorado, Aurora, Colorado, USA | [c] Department of Epidemiology, The University of Iowa, Iowa City, Iowa, USA | [d] National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA | [e] New York State Department of Health, Albany, New York, USA | [f] Department of Neurology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, New York, USA | [g] Physical Medicine and Rehabilitation, School of Medicine, University of Colorado, Aurora, Colorado, USA | [h] Department of Pediatrics, Weill Cornell Medical College, New York, New York, USA
Correspondence: [*] Correspondence to: Jennifer G. Andrews, Department of Pediatrics, University of Arizona, PO Box 245073, Tucson, AZ 85724-5073, USA.Tel.: +1 520 626 6816; Fax: +1 520 626 8056; E-mail: [email protected].
Note: [1] The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Abstract: Dystrophinopathies are caused by mutations in DMD resulting in progressive muscle weakness. They are historically divided into the more severe Duchenne (DMD) and milder Becker (BMD) muscular dystrophy phenotypes. Classification is important for research and clinical care. The purpose of this study was to describe a multi-variable approach to classifying cases from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) and to assess the accuracy of the diagnostic classification scheme. We used age at loss of mobility, molecular testing results, and age at symptom onset to classify cases as having DMD or BMD and to assess sensitivity and specificity. Mobility status showed low sensitivity and high specificity for predicting DMD (65.5% and 99.3%, respectively) and BMD (62.8% and 97.7%, respectively) phenotypes. Molecular testing showed 90.9% sensitivity and 66.4% specificity for DMD; 76.3% sensitivity and 90.0% specificity for BMD. Age of onset predicted DMD with sensitivity of 73.9% and specificity of 69.0%; BMD had 99.7% specificity and 36.7% sensitivity. Mobility status, molecular test results, and age at symptom onset are important but inconsistent measures for accurately classifying individuals into DMD or BMD phenotypes. These results have implications for prognosis in newly diagnosed individuals and for classifying phenotype in clinical trials.
Keywords: Muscular dystrophies, Duchenne, Becker, phenotype, diagnostic accuracy, dystrophinopathy
DOI: 10.3233/JND-180306
Journal: Journal of Neuromuscular Diseases, vol. 5, no. 4, pp. 481-495, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]